These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7883840)

  • 1. Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers.
    Andreotti AC; Pianezzola E; Persiani S; Pacciarini MA; Strolin Benedetti M; Pontiroli AE
    J Clin Endocrinol Metab; 1995 Mar; 80(3):841-5. PubMed ID: 7883840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers.
    Persiani S; Rocchetti M; Pacciarini MA; Holt B; Toon S; Strolin-Benedetti M
    Biopharm Drug Dispos; 1996 Jul; 17(5):443-55. PubMed ID: 8830979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers.
    Persiani S; Sassolas G; Piscitelli G; Bizollon CA; Poggesi I; Pianezzola E; Edwards DM; Strolin Benedetti M
    J Pharm Sci; 1994 Oct; 83(10):1421-4. PubMed ID: 7884663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.
    Mattei AM; Ferrari C; Baroldi P; Cavioni V; Paracchi A; Galparoli C; Romano C; Spellecchia D; Gerevini G; Crosignani PG
    J Clin Endocrinol Metab; 1988 Jan; 66(1):193-8. PubMed ID: 3275684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients.
    Ciccarelli E; Giusti M; Miola C; Potenzoni F; Sghedoni D; Camanni F; Giordano G
    J Clin Endocrinol Metab; 1989 Oct; 69(4):725-8. PubMed ID: 2570790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabergoline.
    Colao A; Lombardi G; Annunziato L
    Expert Opin Pharmacother; 2000 Mar; 1(3):555-74. PubMed ID: 11249538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
    Ciresi A; Amato MC; Guarnotta V; Lo Castro F; Giordano C
    Clin Endocrinol (Oxf); 2013 Dec; 79(6):845-52. PubMed ID: 23506485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients.
    Delgrange E; Daems T; Verhelst J; Abs R; Maiter D
    Eur J Endocrinol; 2009 May; 160(5):747-52. PubMed ID: 19223454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women.
    Melis GB; Gambacciani M; Paoletti AM; Beneventi F; Mais V; Baroldi P; Fioretti P
    J Clin Endocrinol Metab; 1987 Sep; 65(3):541-5. PubMed ID: 3624413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.
    De Rosa M; Colao A; Di Sarno A; Ferone D; Landi ML; Zarrilli S; Paesano L; Merola B; Lombardi G
    Eur J Endocrinol; 1998 Mar; 138(3):286-93. PubMed ID: 9539303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders.
    Ferrari C; Mattei A; Melis GB; Paracchi A; Muratori M; Faglia G; Sghedoni D; Crosignani PG
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1201-6. PubMed ID: 2656736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients.
    Muratori M; Arosio M; Gambino G; Romano C; Biella O; Faglia G
    J Endocrinol Invest; 1997 Oct; 20(9):537-46. PubMed ID: 9413808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cabergoline on metabolism in prolactinomas.
    Auriemma RS; Granieri L; Galdiero M; Simeoli C; Perone Y; Vitale P; Pivonello C; Negri M; Mannarino T; Giordano C; Gasperi M; Colao A; Pivonello R
    Neuroendocrinology; 2013; 98(4):299-310. PubMed ID: 24355865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients.
    Ferrari C; Paracchi A; Romano C; Gerevini G; Boghen M; Barreca A; Fortini P; Dubini A
    Clin Endocrinol (Oxf); 1988 Nov; 29(5):467-76. PubMed ID: 2908102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
    Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.